Ipca Labs - Progressing Steadily To Reclaim The Growth Path: Motilal Oswal

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

We met with the management of Ipca Laboratories Ltd. recently to understand its business outlook.

Domestic formulation is the key driver of its sales growth, fueled by market outperformance in pain/dermatology/urology and supported by higher medical representative base.

Notwithstanding the near-term hiccups in active pharma ingredient segment, Ipca is building levers to almost double its API exports by FY27E.

The exports (branded/generics) formulation sales is likely to revive from FY24.

We have reduced our earnings estimate for FY23/FY24 by 4%/3% to factor in increased opex on the back of promotional activities and logistics cost. After two years of earnings decline, we expect Ipca to clock 33% earnings compound annual growth rate over FY23- 25.

Click on the attachment to read the full report:

Motilal Oswal Ipca Labs Update.pdf

Read Document

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.